<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="96516"><DrugName>delolimogene mupadenorepvec</DrugName><DrugNamesKey><Name id="43119463">delolimogene mupadenorepvec</Name></DrugNamesKey><DrugSynonyms><Name><Value>LOAd-703</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CD40L- and 4-1BBL-expressing oncolytic adenovirus (pancreatic cancer), Lokon Pharma/Uppsala University</Value></Name><Name><Value>delolimogene mupadenorepvec</Value><Types><Type>INN</Type></Types></Name><Name><Value>dual CD40 costimulator/4-1BB costimulator (oncolytic adenovirus delivery, pancreatic cancer), Uppsala University/Lokon Pharma</Value></Name><Name><Value>mLOAd703</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22324">Uppsala University</CompanyOriginator><CompaniesPrimary><Company id="22324">Uppsala University</Company><Company id="1108264">Lokon Pharma AB</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1108264" type="Company"><TargetEntity id="5045871524" type="organizationId">Lokon Pharma AB</TargetEntity></SourceEntity><SourceEntity id="22324" type="Company"><TargetEntity id="5001205357" type="organizationId">Uppsala University</TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2380" type="ciIndication"><TargetEntity id="C67" type="ICD10"></TargetEntity><TargetEntity id="188.9" type="ICD9"></TargetEntity><TargetEntity id="10005003" type="MEDDRA"></TargetEntity><TargetEntity id="-2101107804" type="omicsDisease"></TargetEntity><TargetEntity id="578" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"></TargetEntity><TargetEntity id="10062042" type="MEDDRA"></TargetEntity><TargetEntity id="D008175" type="MeSH"></TargetEntity><TargetEntity id="-243902424" type="omicsDisease"></TargetEntity><TargetEntity id="611" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="767" type="ciIndication"><TargetEntity id="C18" type="ICD10"></TargetEntity><TargetEntity id="10009944" type="MEDDRA"></TargetEntity><TargetEntity id="D003110" type="MeSH"></TargetEntity><TargetEntity id="-729056112" type="omicsDisease"></TargetEntity><TargetEntity id="593" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="5141" type="Action"><TargetEntity id="5150" type="Mechanism">CD40 Agonist</TargetEntity></SourceEntity><SourceEntity id="5450" type="Action"><TargetEntity id="7186" type="Mechanism">Tumor Necrosis Factor Receptor Superfamily Member 9 (TNFRSF9, CD137, 4-1BB) Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00390" type="ciTarget"><TargetEntity id="10957975809583" type="siTarget">Tumor necrosis factor receptor superfamily member 5</TargetEntity><TargetEntity id="48374834835693" type="siTarget">Interleukin-6</TargetEntity><TargetEntity id="122" type="omicsTarget"></TargetEntity><TargetEntity id="410" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00416" type="ciTarget"><TargetEntity id="148692323936043" type="siTarget">Tumor necrosis factor receptor superfamily member 9</TargetEntity><TargetEntity id="2340" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="205">Melanoma</Indication><Indication id="2380">Bladder cancer</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="755">Lung tumor</Indication><Indication id="767">Colon tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsPrimary><ActionsPrimary><Action id="5141">CD40 ligand receptor agonist</Action><Action id="5450">CDw137 agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="173472">Dendritic cell stimulator</Action><Action id="393">Immunostimulant</Action><Action id="7741">B-lymphocyte stimulator</Action><Action id="7751">Macrophage stimulator</Action><Action id="7761">T-lymphocyte stimulator</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="62">Virus recombinant</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="347">Intratumoral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-07-03T05:07:23.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1108264" linkType="Company"&gt;Lokon Pharma AB&lt;/ulink&gt;, in collaboration with &lt;ulink linkID="22324" linkType="Company"&gt;Uppsala University&lt;/ulink&gt;, is developing  delolimogene mupadenorepvec (LOAd-703), a double-armed immunostimulatory oncolytic adenovirus  encoding CD40 ligand (CD40L) and 4-1BBL, for the potential local treatment of pancreatic cancer [&lt;ulink linkID="1648303" linkType="Reference"&gt;1648303&lt;/ulink&gt;]. The company is also investigating LOAd-703, for the potential treatment of cancer including ovarian cancer [&lt;ulink linkID="1954711" linkType="Reference"&gt;1954711&lt;/ulink&gt;]. By September 2015, a phase I/IIa trial was underway for pancreatic cancer [&lt;ulink linkID="1692263" linkType="Reference"&gt;1692263&lt;/ulink&gt;]. In February 2016, another phase I/II trial was initiated in April 2016 [&lt;ulink linkID="1743684" linkType="Reference"&gt;1743684&lt;/ulink&gt;]. In July 2017, a phase I/II trial was planned to initiate in  patients with cancer [&lt;ulink linkID="1954711" linkType="Reference"&gt;1954711&lt;/ulink&gt;]; in March 2019, first data were presented and the trial was ongoing [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;]. In March 2019, a trial of LOAd-703, in combination with checkpoint blockade, in melanoma patients was planned [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Uppsala University is also developing &lt;ulink linkID="65088" linkType="Drug"&gt;AdCD40L&lt;/ulink&gt; as an immunogene therapy.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2015, the US FDA awarded LOAd-703 Orphan designation for the treatment of pancreatic cancer [&lt;ulink linkID="1657166" linkType="Reference"&gt;1657166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In June 2015, the COMP recommended granting the product Orphan designation for the treatment of pancreatic cancer [&lt;ulink linkID="1672875" linkType="Reference"&gt;1672875&lt;/ulink&gt;]. In July 2015, the program was granted orphan drug status for  the treatment of pancreatic cancer [&lt;ulink linkID="1692271" linkType="Reference"&gt;1692271&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2019, it was reported, at the Fourth CHI Immuno-Oncology Europe Summit in London, UK, that a trial of LOAd-703, in combination with checkpoint blockade, in melanoma patients was planned [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2017, a single group assignment, interventional,  open label phase I/II trial (&lt;ulink linkID="306104" linkType="Protocol"&gt;NCT03225989&lt;/ulink&gt;; LOKON002) was planned to  initiate in Sweden in patients (expected n = 50) with    cancer (pancreatic, biliary, colorectal or ovarian) together with the standard of care chemotherapy or using gemcitabine immune-conditioning. At that time, the trial was expected to start in October 2017 and complete in November 2020. In March 2018, LOAd-703 was to be administred at three doses (total viral load - 1x10(11), 5x10(11), 1x10(12) viral particles (VP)) in phase I and the trial was expected to complete in December 2022 [&lt;ulink linkID="1954711" linkType="Reference"&gt;1954711&lt;/ulink&gt;]. In March 2019, first data were presented at the Fourth CHI Immuno-Oncology Europe Summit in London, UK. LOAd-703 was administered in a 3+3 dose escalation phase (n = 41) and an extended phase (n = increased to 50 patients) at the MTD. In cohort one, two patients died before the completion of treatment and one remained on follow-up at 10 months. At that time cohort two  was currently underway [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, an open-label, single-group assigned, phase I/IIa trial (&lt;ulink linkID="255368" linkType="Protocol"&gt;NCT02705196&lt;/ulink&gt;; LOKON001) was planned in the US in April 2016 in patients (expected n = 26) with pancreatic cancer to evaluate safety and efficacy of LOAd-703. At that time, the trial was expected to complete in January 2019; In November 2016, the trial was initiated. At that time, the study was expected to complete in August 2019; in January 2019,  the study was expected to complete in    August  2020 [&lt;ulink linkID="1743684" linkType="Reference"&gt;1743684&lt;/ulink&gt;]. In March 2019, first data were presented at the Fourth CHI Immuno-Oncology Europe Summit in London, UK. Patients were administered in a 3+3 dose-escalation phase (at doses of 5x10(10), 1x10(11) and 5x10(11) VP), plus an extended cohort (n = 17 to 26) to be dosed at the MTD, intratumorally (percutaneously or endoscopically) every other week for six doses. To date 16 patients have been enrolled, and treatment has been conducted in 14 of them. Death occurred in all three patients in the first cohort, two of the four patients in the second cohort, and one of the five patients in the third cohort. In cohort two, the remaining two patients are on follow-up. In cohort three, one patient discontinued treatment and three are on follow-up. Adverse events, which included fever, nausea, cytokine release syndrome and increased liver enzymes, were transient. At that time a further treatment arm was planned  to add to the trial that will assess LOAd-703 in combination with checkpoint blockade [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2015, a phase I/IIa trial was underway for pancreatic cancer [&lt;ulink linkID="1692263" linkType="Reference"&gt;1692263&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, a clinical trial was underway [&lt;ulink linkID="1648303" linkType="Reference"&gt;1648303&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2019, preclinical data were presented at the 2019 AACR Annual Meeting in Atlanta, GA. In mice with established B16-CD46 tumors, mLOAd703 (intratumoral, 1 x 10 [9] IU/mouse/injection) delayed tumor growth; this reduction was even further enhanced in combination with both anti-PD-1 and anti-PD-L1 therapy. The combination therapy increased the infiltration of immune cells in the tumor including CD3+CD8+ T cells, NK cells and CD103+ DCs. Combination therapy also induced a systemic immune response i.e. increase in proinflammatory cytokines (IFNgamma, TNFalpha, IL-27p38), IL-6 upregulation, and increase in chemokines (MCP-1, KC/GRO. MIP-2)  [&lt;ulink linkID="2134200" linkType="Reference"&gt;2134200&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, data from a syngeneic mouse model (B16.hCD46 in C57/BL6 mice) were presented at the Fourth CHI Immuno-Oncology Europe Summit in London, UK. LOAd-703 increased tumor-infiltrating T-cells, NK cells and DCs, and potentiated the effect of CPIs [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, in vitro data were presented at the 2018 ESMO Congress in Munich, Germany. In infected cells, the encoding transgenes induced transgene expression and subsequently an immunogenic phenotype [&lt;ulink linkID="2084535" linkType="Reference"&gt;2084535&lt;/ulink&gt;]. In March 2019, it was reported at the Fourth CHI Immuno-Oncology Europe Summit in London, UK, that in murine B16 cells modified to express human CD46, LOAd-703 infection caused the tumor cells to become immunogenic [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, preclinical data were presented at the 32nd SITC Annual Meeting 2017 in National Harbor, MD. In multiple xenograft mouse models including lung, ovary, pancreas, colon and bladder, LOAd-703 killed tumor cells by oncolysis following infection with high dose virus (100 multiplicity of infection (MOI)) in vitro and in vivo. In tumor cell/PBMC co‐culture, add-on anti‐PD‐1 antibody did not increase tumor cell apoptosis, while combination with OKT3/IL2 significantly enhanced the effect. In tumor cell/PBMC co‐culture, LOAd-703 at a low MOI delayed oncolysis [&lt;ulink linkID="1984215" linkType="Reference"&gt;1984215&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, preclinical data were presented at the 31st SITC Annual Meeting in National Harbor, MD. In T24 xenograft model using nu/nu immuno-deficient mice, treatment with LOAd(-) and LOAd-703 resulted in decrease in tumor growth compared with PBS. Tumor control was faster when TMZ-CD40L was expressed (example: LOAd-703) and at the end point, only one of five animals had tumor growth compared to three of five in the LOAd(-)-treated group, which demonstrated that additional growth control was due to CD40- induced tumor cell death [&lt;ulink linkID="1883987" linkType="Reference"&gt;1883987&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. In immunodeficient mice with established human Panc01 tumors, treatment with LOAd-703 biw for 3 weeks showed a reduction in tumor burden when compared with PBS treated animals [&lt;ulink linkID="1883952" linkType="Reference"&gt;1883952&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, preclinical data were presented at the 13th CIMT Annual Meeting in Mainz, Germany. LOAd-703 transduction effectively killed tumor cells without affecting  normal cells in pancreatic cancer cell lines and healthy exocrine pancreas cells. In a xenograft Nu/Nu/Panc01 model, LOAd-703 (repeated peritumoral injections for six times) effectively controlled tumor cell growth and maintained complete responses [&lt;ulink linkID="1666990" linkType="Reference"&gt;1666990&lt;/ulink&gt;]. In September 2015, preclinical data were presented at the Joint ESGCT/FSCT congress in Helsinki, Finland. LOAd-703 showed growth control and complete responses in xenograft Nu/Nu/Panc01 model and this effect was enhanced by gemcitabine in xenograft mice and syngeneic C57BL/6/Panc02 models. LOAd-703-transduced dentritic cells pulsed with pp65-CMV peptides significantly expanded antigen-specific T cells and NK cells [&lt;ulink linkID="1718631" linkType="Reference"&gt;1718631&lt;/ulink&gt;]. In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. In the Panc01 Nu/Nu xenograft model, LOAd-703 cured mice from established pancreatic tumors. Activation of endothelial cells by LOAd-703 resulted in recruitment of lymphocytes. LOAd-703 significantly reduced the ability of stellate cells to induce desmoplasia by in LAP-TGF-beta1 and collagen type 1 production [&lt;ulink linkID="1754825" linkType="Reference"&gt;1754825&lt;/ulink&gt;]. &amp;gt;In May 2016, preclinical data were presented at the 19th Annual ASGCT Meeting in Washington DC.  Tumor cell death was efficiently induced within 48 to 72 h post LOAd-703 infection of panel of pancreatic cancer cell lines. In murine xenograft and syngeneic models, LOAd-703 controlled pancreatic tumor growth  [&lt;ulink linkID="1758583" linkType="Reference"&gt;1758583&lt;/ulink&gt;]. In March 2019, similar data at the Fourth CHI Immuno-Oncology Europe Summit in London, UK, pancreatic cancer was chosen as the target for clinical development of the therapy [&lt;ulink linkID="2134921" linkType="Reference"&gt;2134921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA. LOAd-703 as a single agent and also in combination with gemcitabine potently killed pancreatic cancer cells and activated Th1 immunity [&lt;ulink linkID="1648303" linkType="Reference"&gt;1648303&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Delolimogene mupadenorepvec is an oncolytic adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with  human transgenes encoding CD40L and full length 4-1BBL [&lt;ulink linkID="1648303" linkType="Reference"&gt;1648303&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22324">Uppsala University</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-09-08T00:00:00.000Z</StatusDate><Source id="1692263" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1108264">Lokon Pharma AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-09-08T00:00:00.000Z</StatusDate><Source id="1692263" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22324">Uppsala University</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-12T00:00:00.000Z</StatusDate><Source id="1984215" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22324">Uppsala University</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-20T00:00:00.000Z</StatusDate><Source id="1954711" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1108264">Lokon Pharma AB</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-04T00:00:00.000Z</StatusDate><Source id="1657166" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1108264">Lokon Pharma AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-20T00:00:00.000Z</StatusDate><Source id="2134921" type="CONFERENCE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22324">Uppsala University</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="767">Colon tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-12T00:00:00.000Z</StatusDate><Source id="1984215" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22324">Uppsala University</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-20T00:00:00.000Z</StatusDate><Source id="2134921" type="CONFERENCE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22324">Uppsala University</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-12T00:00:00.000Z</StatusDate><Source id="1984215" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1108264">Lokon Pharma AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-19T00:00:00.000Z</StatusDate><Source id="1648303" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22324">Uppsala University</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-19T00:00:00.000Z</StatusDate><Source id="1648303" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1108264">Lokon Pharma AB</OwnerCompany><Country id="EU">EU</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-28T00:00:00.000Z</MileStoneDate><Source id="1692271" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1108264">Lokon Pharma AB</OwnerCompany><Country id="EU">EU</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-18T00:00:00.000Z</MileStoneDate><Source id="1672875" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1108264">Lokon Pharma AB</OwnerCompany><Country id="US">US</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-04T00:00:00.000Z</MileStoneDate><Source id="1657166" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00390"><Name>CD40 ligand receptor</Name><SwissprotNumbers><Swissprot>P25942</Swissprot><Swissprot>P27512</Swissprot><Swissprot>Q28203</Swissprot><Swissprot>Q7YRL5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00416"><Name>CDw137</Name><SwissprotNumbers><Swissprot>P20334</Swissprot><Swissprot>Q07011</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1108264">Lokon Pharma AB</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22324">Uppsala University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="154336" title="Uppsala University and Lokon Pharma to develop LOAd-703 against pancreatic cancer  "></Deal></Deals><PatentFamilies><PatentFamily id="3050918" number="WO-2015155174" title="New medical agents and uses thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lokon Pharma AB" id="1108264"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nexttobe Ab" id="1111061"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Uppsala University" id="22324"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>